Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced a collaboration with TARA Mind, in partnership with Veterans Exploring Treatment Solutions (VETS), to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting major depressive disorder. This initiative aims to expand mental health awareness within the veteran community while advancing the development of HLP003, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
The partnership leverages the networks of TARA Mind and VETS to enhance veteran engagement in clinical trials. This aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness, underscoring the importance of addressing unmet mental health needs among veterans. Helus Pharma is advancing its HLP003 program and broader pipeline of novel serotonergic agonists (NSAs) designed to activate serotonin pathways that promote neuroplasticity.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company focused on developing proprietary NSAs for depression, anxiety, and other mental health conditions. The company’s lead candidates include HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder, which is in Phase 2 development. The company operates in Canada, the United States, the United Kingdom, and Ireland.
The collaboration with TARA Mind and VETS is expected to improve recruitment efforts for the Phase 3 PARADIGM trial, which evaluates HLP003 as an adjunctive treatment for major depressive disorder. By engaging the veteran community, Helus aims to address the high prevalence of mental health conditions among this population. The partnership also supports broader awareness and education about mental health treatment options.
For more details on the partnership, view the full press release at https://ibn.fm/o9dCH. Additional information about Helus Pharma and its pipeline can be found at www.helus.com. The company also provides updates on X, LinkedIn, YouTube, and Instagram.
This announcement follows Helus Pharma’s receipt of FDA Breakthrough Therapy Designation for HLP003, which accelerates the development and regulatory review of drugs intended to treat serious conditions with preliminary clinical evidence indicating substantial improvement over existing therapies. The PARADIGM program represents a significant step in addressing the large unmet need for effective treatments for major depressive disorder, particularly in populations such as veterans who face unique challenges.
